1610680-02-8Relevant articles and documents
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent
Liu, Yong,Laufer, Radoslaw,Patel, Narendra Kumar,Ng, Grace,Sampson, Peter B.,Li, Sze-Wan,Lang, Yunhui,Feher, Miklos,Brokx, Richard,Beletskaya, Irina,Hodgson, Richard,Plotnikova, Olga,Awrey, Donald E.,Qiu, Wei,Chirgadze, Nickolay Y.,Mason, Jacqueline M.,Wei, Xin,Lin, Dan Chi-Chia,Che, Yi,Kiarash, Reza,Fletcher, Graham C.,Mak, Tak W.,Bray, Mark R.,Pauls, Henry W.
supporting information, p. 671 - 675 (2016/07/26)
This work describes a scaffold hopping exercise that begins with known imidazo[1,2-a]pyrazines, briefly explores pyrazolo[1,5-a][1,3,5]triazines, and ultimately yields pyrazolo[1,5-a]pyrimidines as a novel class of potent TTK inhibitors. An X-ray structure of a representative compound is consistent with 11/2 type inhibition and provides structural insight to aid subsequent optimization of in vitro activity and physicochemical and pharmacokinetic properties. Incorporation of polar moieties in the hydrophobic and solvent accessible regions modulates physicochemical properties while maintaining potency. Compounds with enhanced oral exposure were identified for xenograft studies. The work culminates in the identification of a potent (TTK Ki = 0.1 nM), highly selective, orally bioavailable anticancer agent (CFI-402257) for IND enabling studies.
